As illustrated in Fig. 4 and Table S4, according to the IVW method, both CD62L − myeloid DC (OR: 0.751, P = 2.94 × 10−5, q = 0.003) and CD62L − DC (OR: 0.879, P = 1.15 × 10−2, q = 0.194) consistently exhibited a negative correlation with drug-induced osteonecrosis risk. Here, SELL is linked to osteonecrosis.